The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy

Author： Carmichael James   Harris Adrian  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.53, Iss.2, 2004-02, pp. : 123-128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Low-Dose Oral Granisetron (1 mg) plus Intravenous Dexamethasone: Efficacy in Gynecologic Cancer Patients Receiving Carboplatin-Based Chemotherapy

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 71, Iss. 1, 1998-10 ,pp. : 113-115

Elsevier

Access to resources Recommend Favorite

A Double-blind, Randomised Comparison of the Anti-emetic Efficacy of Two Intravenous Doses of Dolasetron Mesilate and Granisetron in Patients Receiving High Dose Cisplatin Chemotherapy

By on behalf of the European Dolasetron Comparative Study Group   Audhuy B.   Cappelaere P.   Martin M.   Cervantes A.   Fabbro M.   Riviere A.   Khayat D.   Bleiberg H.   Faraldi M.   Claverie N.  

European Journal of Cancer, Vol. 32, Iss. 5, 1996-05 ,pp. : 807-813

Elsevier

Access to resources Recommend Favorite

The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

By Yu Zhaocai  

Supportive Care in Cancer, Vol. 17, Iss. 1, 2009-01 ,pp. : 99-102

Springer Publishing Company

Access to resources Recommend Favorite

A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy

By Komada Y.   Matsuyama T.   Takao A.   Hongo T.   Nishimura Y.   Horibe K.   Sakurai M.  

European Journal of Cancer, Vol. 35, Iss. 7, 1999-07 ,pp. : 1095-1101

Elsevier

Access to resources Recommend Favorite

Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant

By Schuster Michael  

Supportive Care in Cancer, Vol. 16, Iss. 5, 2008-05 ,pp. : 477-483

Springer Publishing Company

Access to resources Recommend Favorite